-
Evolving Role of Viltolarsen for Treatment of Duchenne Muscular Dystrophy Adv. Ther. (IF 3.8) Pub Date : 2024-04-01
Abstract Duchenne muscular dystrophy (DMD) is one of the most prevalent X-linked inherited neuromuscular disorders, with an estimated incidence between 1 in 3500 and 5000 live male births. The median life expectancy at birth is around 30 years due to a rapid and severe disease progression. Currently, there is no cure for DMD, and the standard of care is mainly palliative therapy and glucocorticoids
-
‘Totality of Evidence’ Approach in the Development of GP2017, an Approved Adalimumab Biosimilar Adv. Ther. (IF 3.8) Pub Date : 2024-03-21 Norman Gaylis, Charlotte Both, Lena Lemke, Oliver von Richter, Paul Yamauchi
-
Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review Adv. Ther. (IF 3.8) Pub Date : 2024-03-21 Mustafa Khasraw, Priyanka Yalamanchili, Anu Santhanagopal, Chuntao Wu, Maribel Salas, Jie Meng, Maha Karnoub, Stephen Esker, Enriqueta Felip
-
Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300 Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study Adv. Ther. (IF 3.8) Pub Date : 2024-03-21 Eun-Gyoung Hong, Kyung-Wan Min, Jung Soo Lim, Kyu-Jeung Ahn, Chul Woo Ahn, Jae-Myung Yu, Hye Soon Kim, Hyun Jin Kim, Won Kim, Dong Han Kim, Hak Chul Jang
-
Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor Adv. Ther. (IF 3.8) Pub Date : 2024-03-18 Gilles Salles, Jenny M. H. Chen, Ina Zhang, Fabio Kerbauy, James J. Wu, Sally W. Wade, Ana Nunes, Chaoling Feng, Ioana Kloos, Weimin Peng, Julia T. Snider, Dylan Maciel, Keith Chan, Sam Keeping, Bijal Shah
-
Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data Adv. Ther. (IF 3.8) Pub Date : 2024-03-18 Brian G. M. Durie, Shaji K. Kumar, Eric M. Ammann, Alex Z. Fu, Shuchita Kaila, Annette Lam, Saad Z. Usmani, Thierry Facon
-
Enhancing Drug Management, Cost Savings, and Staff Satisfaction in Anesthesiology: A Quality Improvement Project in a Chinese Tertiary Hospital Adv. Ther. (IF 3.8) Pub Date : 2024-03-18 Xiaomin Xing, Haijun Qu, Longyuan Wang, Xiaojia Hao, Yalan Zhong, Fanbo Jing
-
Correction to: PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly Adv. Ther. (IF 3.8) Pub Date : 2024-03-13 Dermot O’Toole, Pamela L. Kunz, Susan M. Webb, Grace Goldstein, Sheila Khawaja, Mark McDonnell, Sandra Boiziau, Delphine Gueguen, Aude Houchard, Antonio Ribeiro-Oliveira, Ally Prebtani
-
Adverse Drug Events Observed with the Newly Approved Remimazolam in Comparison to Propofol for General Anesthesia in Patients Undergoing Surgery: A Meta-analysis Adv. Ther. (IF 3.8) Pub Date : 2024-03-13 Lidan Huang, Hong Liu, Xue Zou, Jiawang Ding, Song Tao
-
Perioperative and Long-Term Outcomes in Patients Undergoing Synchronous Carotid Endarterectomy and Coronary Artery Bypass Grafting: A Single-Center Experience Adv. Ther. (IF 3.8) Pub Date : 2024-03-13
Abstract Introduction Patients requiring coronary artery bypass grafting (CABG) and carotid endarterectomy (CEA) can be managed with staged (CEA before CABG), reverse staged (CABG before CEA) or synchronous treatment. This single-center retrospective study evaluated the outcomes in patients undergoing planned synchronous CEA and CABG. Methods Between 2000 and 2020 a total of 185 patients with symptomatic
-
Comparison of Healthcare Costs for Women with Treated Versus Untreated Vasomotor Symptoms Due to Menopause Adv. Ther. (IF 3.8) Pub Date : 2024-03-11 Aki Shiozawa, Shayna Mancuso, Christopher Young, Jennifer Friderici, Summer Tran, Helen M. Trenz
-
The Humanistic and Economic Burden Associated with Major Depressive Disorder: A Retrospective Cross-Sectional Analysis Adv. Ther. (IF 3.8) Pub Date : 2024-03-11
Abstract Introduction Major depressive disorder (MDD) is a debilitating and costly condition. This analysis characterized the health-related quality of life (HRQoL), health care resource utilization (HCRU), and costs between patients with versus without MDD, and across MDD severity levels. Methods The 2019 National Health and Wellness Survey was used to identify adults with MDD, who were stratified
-
Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review Adv. Ther. (IF 3.8) Pub Date : 2024-03-11
Abstract Adalimumab (ADL, Humira®, reference product), an anti-TNF-α biologic, has transformed the treatment of chronic, immune-mediated inflammatory diseases. However, the high cost of ADL therapy has driven the development of more affordable ADL biosimilars, agents with no clinically meaningful differences from the reference product. This review summarizes the product attributes of reference ADL
-
Efficacy and Safety of Transitioning to Lemborexant from Z-drug, Suvorexant, and Ramelteon in Japanese Insomnia Patients: An Open-label, Multicenter Study Adv. Ther. (IF 3.8) Pub Date : 2024-03-09 Motohiro Ozone, Susumu Hirota, Yu Ariyoshi, Kenichi Hayashida, Azusa Ikegami, Mitsunari Habukawa, Hayato Ohshima, Daisuke Harada, Hiroshi Hiejima, Nozomu Kotorii, Kenta Murotani, Takehiro Taninaga, Naohisa Uchimura
-
Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT Adv. Ther. (IF 3.8) Pub Date : 2024-03-05
Abstract Background Bullous pemphigoid (BP) is a rare, autoimmune, blistering skin disease associated with high disease burden, profoundly decreased quality of life and increased morbidity. Emerging evidence supports an important role for type 2 inflammation in disease pathogenesis. Current management relies on topical and/or systemic corticosteroids, non-selective immunosuppressants and antibiotics
-
Patient and Clinician Perspectives: To Create a Better Future for Chronic Kidney Disease, We Need to Talk About Our Kidneys Adv. Ther. (IF 3.8) Pub Date : 2024-03-05
Abstract Chronic kidney disease (CKD) affects more than one in ten people worldwide. However, results from the REVEAL-CKD study suggest that it is often not diagnosed. Many patients are therefore unaware that they have CKD, putting them at increased risk of disease progression and complications. Empowering patients with knowledge about CKD will allow them to become active participants in their own
-
Left Atrial Strain Insights in Atrial Fibrillation and the Interplay with Metabolic Syndrome Adv. Ther. (IF 3.8) Pub Date : 2024-03-05 Hyun-Jin Kim, Hyun-Sun Kim
-
An Update on Stiripentol Mechanisms of Action: A Narrative Review Adv. Ther. (IF 3.8) Pub Date : 2024-03-05 Alexandre Bacq, Antoine Depaulis, Vincent Castagné, Marie-Emmanuelle Le Guern, Elaine C. Wirrell, Marc Verleye
-
Incidence and Costs of Clinically Significant Events with Systemic Therapy in Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study Adv. Ther. (IF 3.8) Pub Date : 2024-03-05
Abstract Introduction Systemic therapies have been associated with clinically significant events (CSEs) in patients with unresectable hepatocellular carcinoma (uHCC). We evaluated the incidence of CSEs (bleeding, clotting, encephalopathy, and portal hypertension), and their impact on healthcare resource utilization (HCRU) and costs, in patients with uHCC treated with first-line (1L) atezolizumab plus
-
Increased Nasal Blimp1 + Treg Cells After Sublingual Immunotherapy Reflect the Efficacy of Treatment in Allergic Rhinitis Adv. Ther. (IF 3.8) Pub Date : 2024-03-05 Yue Pan, Xinxin Zhang, Huanting Geng, Yan Yu, Jianyong Liu, Menglin Li, Huijun Yang, Yifang Yuan, Yao Xu, Yujia Wu, Geping Wu, Xingkai Ma, Lei Cheng
-
Satisfaction with the Injection Experience of a New, Citrate-Free Formulation of Ixekizumab Adv. Ther. (IF 3.8) Pub Date : 2024-03-05 Sanjay Chabra, Julie Birt, Rebecca Bolce, Jeffrey Lisse, William N. Malatestinic, Baojin Zhu, Miriam Kimel, Julie McCormack, Marissa Stefan, W. Chad Cragun
-
Treatment Patterns with Mirabegron and Antimuscarinics for Overactive Bladder: A Prospective, Registry Study in Taiwan and South Korea (FAITH) Adv. Ther. (IF 3.8) Pub Date : 2024-03-02 Seung-June Oh, Sung Tae Cho, Hann-Chorng Kuo, Eric Chieh-Lung Chou, Yu-Chao Hsu, Kyu-Sung Lee, Farid Hadi, Yi Song, Budiwan Sumarsono
-
Selective Internal Radiation Therapy Using Y-90 Resin Microspheres for Metastatic Colorectal Cancer: An Updated Systematic Review and Network Meta-Analysis Adv. Ther. (IF 3.8) Pub Date : 2024-02-26 André L. F. Azeredo-da-Silva, Victor Hugo F. de Jesus, Ion Agirrezabal, Victoria K. Brennan, Phuong L. Carion, Nathalie Amoury, Bruna M. Vetromilla, Bruna S. Zanotto, Suki Shergill, Patricia K. Ziegelmann
-
Correction to: Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia Adv. Ther. (IF 3.8) Pub Date : 2024-02-20 Tawfeg Ben-Omran, Luis Masana, Genovefa Kolovou, Gema Ariceta, F. Javier Nóvoa, Allan M. Lund, Martin P. Bogsrud, María Araujo, Osamah Hussein, Daiana Ibarretxe, Rosa M. Sanchez-Hernández, Raul D. Santos
-
Managing Gastrointestinal Symptoms Resulting from Treatment with Trofinetide for Rett Syndrome: Caregiver and Nurse Perspectives Adv. Ther. (IF 3.8) Pub Date : 2024-02-20 Rebecca Moore, Joshua Poulsen, Lindsay Reardon, Candice Samples-Morris, Holly Simmons, Keri M. Ramsey, Meagan L. Whatley, Jane B. Lane
Rett syndrome (RTT) is a rare genetic neurodevelopmental disorder mainly affecting female individuals. Trofinetide was recently approved as the first treatment for RTT, largely on the basis of results from the phase 3 LAVENDER trial, in which trofinetide showed improvements in core symptoms of RTT compared with placebo. However, gastrointestinal (GI) symptoms such as diarrhea and vomiting were commonly
-
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Phase 3 Roxadustat Trials in Japan Adv. Ther. (IF 3.8) Pub Date : 2024-02-16 Takayuki Hamano, Yusuke Yamaguchi, Kashia Goto, Sho Mizokawa, Yuichiro Ito, Frank Dellanna, Jonathan Barratt, Tadao Akizawa
-
Exposure–Response Efficacy Modeling to Support Trofinetide Dosing in Individuals with Rett Syndrome Adv. Ther. (IF 3.8) Pub Date : 2024-02-16 Mona Darwish, Julie Passarell, James M. Youakim, Heather Bradley, Kathie M. Bishop
-
Lutein and Zeaxanthin Supplementation Improves Dynamic Visual and Cognitive Performance in Children: A Randomized, Double-Blind, Parallel, Placebo-Controlled Study Adv. Ther. (IF 3.8) Pub Date : 2024-02-16 Rajesh Parekh, Billy R. Hammond, Divya Chandradhara
-
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 Trials Adv. Ther. (IF 3.8) Pub Date : 2024-02-16 Takayuki Hamano, Yusuke Yamaguchi, Kashia Goto, Shaka Martin, Alina Jiletcovici, Frank Dellanna, Tadao Akizawa, Jonathan Barratt
-
7-Year Efficacy and Safety of iStent inject Trabecular Micro-Bypass in Combined and Standalone Usage Adv. Ther. (IF 3.8) Pub Date : 2024-02-16
Abstract Introduction This study evaluated 7-year effectiveness and safety of second-generation trabecular micro-bypass implantation (iStent inject) either in combination with cataract surgery or as a standalone procedure (Combined or Standalone subgroups, respectively) in eyes with open-angle glaucoma. Methods This prospective, non-randomized, unmasked, longitudinal study included 125 consecutive
-
Development of a Conceptual Model for the Patient Experience of Immunoglobulin A Nephropathy (IgAN): A Qualitative Literature Review Adv. Ther. (IF 3.8) Pub Date : 2024-02-16 Natalie V. J. Aldhouse, Helen Kitchen, Tamara Al-Zubeidi, Madeleine Thursfield, Randall Winnette, Sandi See Tai, Linda Zhu, Cecilia Freitas, Nicolas Garnier, Christine L. Baker
-
Assessing Itch Severity: Content Validity and Psychometric Properties of a Patient-Reported Pruritus Numeric Rating Scale in Atopic Dermatitis Adv. Ther. (IF 3.8) Pub Date : 2024-02-16 Alissa Rams, Jessica Baldasaro, Laurine Bunod, Laure Delbecque, Sara Strzok, Juliette Meunier, Hany ElMaraghy, Luna Sun, Evangeline Pierce
-
Cost-Effectiveness Analysis of Sintilimab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: A Societal Perspective Adv. Ther. (IF 3.8) Pub Date : 2024-02-15 Fuming Li, Yingyao Chen, Dunming Xiao, Shan Jiang, Yi Yang
-
Application of Northern Goshawk Back-Propagation Artificial Neural Network in the Prediction of Monohydroxycarbazepine Concentration in Patients with Epilepsy Adv. Ther. (IF 3.8) Pub Date : 2024-02-15
Abstract Introduction A northern goshawk back-propagation artificial neural network (NGO-BPANN) model was established to predict monohydroxycarbazepine (MHD) concentration in patients with epilepsy. Methods The data were collected from 108 Han Chinese patients with epilepsy on oxcarbazepine monotherapy. The results of 14 genotype variates were selected as the input layer in the first BPANN model, and
-
Efficacy and Tolerability of Adjunctive Brivaracetam in Patients with Focal-Onset Seizures on Specific Concomitant Antiseizure Medications: Pooled Analysis of Double-Blind, Placebo-Controlled Trials Adv. Ther. (IF 3.8) Pub Date : 2024-02-15 Brian Moseley, Dimitrios Bourikas, Svetlana Dimova, Sami Elmoufti, Simon Borghs
-
Respiratory Syncytial Virus (RSV) Burden in Infants in the Kingdom of Saudi Arabia and the Impact of All-Infant RSV Protection: A Modeling Study Adv. Ther. (IF 3.8) Pub Date : 2024-02-15 Adel Alharbi, Abdullah Yousef, Amal Zubani, Mohammad Alzahrani, Mohammad Al-Hindi, Saleh Alharbi, Turki Alahmadi, Hana Alabdulkarim, Paulina Kazmierska, Matthieu Beuvelet
-
Exploring Perceptions of Biologic Therapies: A Qualitative Study Among Canadians Living with Severe Asthma Adv. Ther. (IF 3.8) Pub Date : 2024-02-13 Andrea Bever, Jessica Dunne, Jenna Reynolds, Susan Waserman, Alan G. Kaplan, Andrew O’Keefe, Stacey McNeilly, Shelagh M. Szabo
-
Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase 4 Inhibitor Adv. Ther. (IF 3.8) Pub Date : 2024-02-10 Marc Evans, Mansoor Husain, Ayush Srivastava, Kamal Kant Mangla, Anja Birk Kuhlman, Ildiko Lingvay
-
Cost-Effectiveness Analysis of HRD Testing for Previously Treated Patients with Advanced Ovarian Cancer in Italy Adv. Ther. (IF 3.8) Pub Date : 2024-02-08 Carla Rognoni, Domenica Lorusso, Francesco Costa, Patrizio Armeni
-
Contraceptive Recommendations for Women with Immune-Mediated Inflammatory Diseases: A Delphi Consensus Adv. Ther. (IF 3.8) Pub Date : 2024-02-07 José Manuel Carrascosa, Ana Echarri, Olga Gavín Sebastián, Paloma García de la Peña, Oscar Martínez Pérez, Susan Ramirez, Mónica Valderrama, María Montoro Álvarez
-
The Association Between Short-Acting β2-Agonist Over-Prescription, and Patient-Reported Acquisition and Use on Asthma Control and Exacerbations: Data from Australia Adv. Ther. (IF 3.8) Pub Date : 2024-02-04 David Price, Christine Jenkins, Kerry Hancock, Rebecca Vella, Florian Heraud, Porsche Le Cheng, Ruth Murray, Maarten Beekman, Sinthia Bosnic-Anticevich, Fabio Botini, Victoria Carter, Angelina Catanzariti, Joe Doan, Kirsty Fletton, Ata Kichkin, Thao Le, Chantal Le Lievre, Chi Ming Lau, Dominique Novic, John Pakos, Kanchanamala Ranasinghe, Alexander Roussos, Josephine Samuel-King, Anita Sharma, Deb
-
Efficacy and Safety of Esaxerenone in Hypertensive Patients with Left Ventricular Hypertrophy (ESES-LVH) Study: A Multicenter, Open-Label, Prospective, Interventional Study Adv. Ther. (IF 3.8) Pub Date : 2024-02-04 Eiichiro Yamamoto, Hiroki Usuku, Daisuke Sueta, Satoru Suzuki, Taishi Nakamura, Kunihiko Matsui, Kenichi Matsushita, Tomoko Iwasaki, Naritsugu Sakaino, Toshihiko Sakanashi, Kazuto Hirayama, Hirofumi Kurokawa, Koichi Kikuta, Nobuyasu Yamamoto, Koji Sato, Takanori Tokitsu, Takashi Taguchi, Kazuhito Shiosakai, Kotaro Sugimoto, Kenichi Tsujita
-
Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Adv. Ther. (IF 3.8) Pub Date : 2024-02-04 Meredith McCormack, Rosirene Paczkowski, Noelle N. Gronroos, Stephen G. Noorduyn, Lydia Lee, Phani Veeranki, Mary G. Johnson, Emmeline Igboekwe, Kristin Kahle-Wrobleski, Reynold Panettieri
-
Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis Adv. Ther. (IF 3.8) Pub Date : 2024-02-02 Andrew Ip, Alex Mutebi, Tongsheng Wang, Monika Jun, Anupama Kalsekar, Fernando Rivas Navarro, Anthony Wang, Rajesh Kamalakar, Mariana Sacchi, Brian Elliott
-
Effect of Individual Patient Characteristics and Treatment Choices on Reliever Medication Use in Moderate-Severe Asthma: A Poisson Analysis of Randomised Clinical Trials Adv. Ther. (IF 3.8) Pub Date : 2024-02-01 Sven C. van Dijkman, Arzu Yorgancıoğlu, Ian Pavord, Guy Brusselle, Paulo M. Pitrez, Sean Oosterholt, Sourabh Fumali, Anurita Majumdar, Oscar Della Pasqua
-
Can the Evidence-Based Use of Probiotics (Notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) Mitigate the Clinical Effects of Antibiotic-Associated Dysbiosis? Adv. Ther. (IF 3.8) Pub Date : 2024-01-30 Dan Waitzberg, Francisco Guarner, Iva Hojsak, Gianluca Ianiro, D. Brent Polk, Harry Sokol
-
Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study Adv. Ther. (IF 3.8) Pub Date : 2024-01-30 Michael Lehrke, Anja Vogt, Volker Schettler, Matthias Girndt, Uwe Fraass, Anja Tabbert-Zitzler, Ian Bridges, Nafeesa N. Dhalwani, Kausik K. Ray
-
Artificial Intelligence in Liver Diseases: Recent Advances Adv. Ther. (IF 3.8) Pub Date : 2024-01-29 Feifei Lu, Yao Meng, Xiaoting Song, Xiaotong Li, Zhuang Liu, Chunru Gu, Xiaojie Zheng, Yi Jing, Wei Cai, Kanokwan Pinyopornpanish, Andrea Mancuso, Fernando Gomes Romeiro, Nahum Méndez-Sánchez, Xingshun Qi
Liver diseases cause a significant burden on public health worldwide. In spite of great advances during recent years, there are still many challenges in the diagnosis and treatment of liver diseases. During recent years, artificial intelligence (AI) has been widely used for the diagnosis, risk stratification, and prognostic prediction of various diseases based on clinical datasets and medical images
-
Roxadustat and Oral Iron Absorption in Chinese Patients with Anemia of Chronic Kidney Disease: A Randomized, Open-Label, Phase 4 Study (ALTAI) Adv. Ther. (IF 3.8) Pub Date : 2024-01-27 Haiting Wu, Hong Cheng, Caili Wang, Li Yao, Shuguang Qin, Li Zuo, Zhao Hu, Chun Zhang, Yiqing Wu, Alexis Hofherr, Katie Mohan, Stephen Rush, Xuemei Li
-
The Cost of Seasonal Influenza: A Systematic Literature Review on the Humanistic and Economic Burden of Influenza in Older (≥ 65 Years Old) Adults Adv. Ther. (IF 3.8) Pub Date : 2024-01-23 Jakob Langer, Verna L. Welch, Mary M. Moran, Alejandro Cane, Santiago M. C. Lopez, Amit Srivastava, Ashley Enstone, Amy Sears, Kristen Markus, Maria Heuser, Rachel Kewley, Isabelle Whittle
Introduction Adults aged ≥ 65 years contribute a large proportion of influenza-related hospitalizations and deaths due to increased risk of complications, which result in high medical costs and reduced health-related quality of life (HRQoL). Although seasonal influenza vaccines are recommended for older adults, the effectiveness of current vaccines is dependent on several factors including strain matching
-
Autologous Skin Cell Suspension for Full-Thickness Skin Defect Reconstruction: Current Evidence and Health Economic Expectations Adv. Ther. (IF 3.8) Pub Date : 2024-01-22 Steven A. Kahn, Jeffrey E. Carter, Shelby Wilde, Aleisha Chamberlain, Thomas P. Walsh, Jeremiah A. Sparks
Despite differing etiologies, acute thermal burn injuries and full-thickness (FT) skin defects are associated with similar therapeutic challenges. When not amenable to primary or secondary closure, the conventional standard of care (SoC) treatment for these wound types is split-thickness skin grafting (STSG). This invasive procedure requires adequate availability of donor skin and is associated with
-
Burden of Illness of Type 2 Diabetes Mellitus in the Kingdom of Saudi Arabia: A Five-Year Longitudinal Study Adv. Ther. (IF 3.8) Pub Date : 2024-01-19 Mohammed AlHarbi, Abdullah Othman, Ahmed Ali Nahari, Ahmed Hamdan Al-Jedai, Daniel Cuadras, Faisal Almalky, Fayez AlAzmi, Hajer Yousef Almudaiheem, Hamad AlShubrumi, Hameed AlSwat, Homaid AlSahafi, Kamelia Sindi, Khadija Basaikh, Majed AlQahtani, Mark Lamotte, Moataz Yahia, Mohamed El-Khedr Hassan, Mohammed AlMutlaq, Mohammed AlRoaly, Somaya AlZelaye, Zein AlGhamdi
-
Dapagliflozin Utilization in Chronic Kidney Disease and Its Real-World Effectiveness Among Patients with Lower Levels of Albuminuria in the USA and Japan Adv. Ther. (IF 3.8) Pub Date : 2024-01-19
Abstract Introduction Sodium–glucose cotransporter 2 inhibitors such as dapagliflozin have been proven effective for slowing chronic kidney disease (CKD) progression in large outcomes trials that mainly included patients with higher levels of albuminuria. Understanding the real-world utilization and effectiveness of these drugs among patients with CKD with lower levels of albuminuria can inform clinical
-
Assessing the Burden and Cost of COVID-19 Across Variants in Commercially Insured Immunocompromised Populations in the United States: Updated Results and Trends from the Ongoing EPOCH-US Study Adv. Ther. (IF 3.8) Pub Date : 2024-01-13 Amita Ketkar, Vincent Willey, Lisa Glasser, Casey Dobie, Cachet Wenziger, Chia-Chen Teng, Christine Dube, Sunny Hirpara, Dennis Cunningham, Monica Verduzco-Gutierrez
-
Real-World Management of Patients with Pulmonary Arterial Hypertension: Insights from EXPOSURE Adv. Ther. (IF 3.8) Pub Date : 2024-01-13 Audrey Muller, Pilar Escribano-Subias, Catarina C. Fernandes, Martina Fontana, Tobias J. Lange, Stefan Söderberg, Sean Gaine
-
Bladder Cancer, Loss of Y Chromosome, and New Opportunities for Immunotherapy Adv. Ther. (IF 3.8) Pub Date : 2024-01-10 Arun K. Mankan, Nagender Mankan, Begona de las Heras, Shakti H. Ramkissoon, Olga Bodriagova, Laura Vidal, Enrique Grande, Kamal S. Saini
-
Ralinepag Phase II Open-Label Extension Study in Patients with Pulmonary Arterial Hypertension Adv. Ther. (IF 3.8) Pub Date : 2024-01-10 Joan Barberà, Pavel Jansa, Elizabeth Klings, Arsen Ristić, Anne Keogh, Derek Solum, Youlan Rao, Rob Grover, Isil Saib, Namita Sood
-
Correction to: Treatment-Related Cognitive Impairment in Patients with Prostate Cancer: Patients’ Real-World Insights for Optimizing Outcomes Adv. Ther. (IF 3.8) Pub Date : 2024-01-11 Bruce A. Cowan, Kara Olivier, Bertrand Tombal, Jeffrey S. Wefel
-
Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis Adv. Ther. (IF 3.8) Pub Date : 2024-01-09 Amy S. Paller, Andreas Pinter, Lara Wine Lee, Roland Aschoff, Jacek Zdybski, Christina Schnopp, Amy Praestgaard, Ashish Bansal, Brad Shumel, Randy Prescilla, Mike Bastian
-
Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b Study Adv. Ther. (IF 3.8) Pub Date : 2024-01-08 Emma Guttman-Yassky, Eric L. Simpson, Kristian Reich, Kenji Kabashima, Ken Igawa, Tetsuya Suzuki, Hirotaka Mano, Takeshi Matsui, Ehsanollah Esfandiari, Masutaka Furue